Palbociclib (PD-0332991) HCl Licensed by Pfizer

Catalog No.S1116

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Palbociclib (PD-0332991) HCl Chemical Structure

Palbociclib (PD-0332991) HCl Chemical Structure
Molecular Weight: 483.99

Validation & Quality Control

6 customer reviews :

Quality Control & MSDS

Related Compound Libraries

CDK Inhibitors with Unique Features

  • Pan CDK Inhibitor

    BAY 1000394 Pan-CDK1/2/3/4/7/9 inhibitor, IC50=5-25 nM.

  • Most Potent CDK Inhibitor

    LY2835219 CDK4, IC50=2 nM; CDK6, IC50=10 nM.

  • CDK Inhibitor in Clinical Trial

    Dinaciclib (SCH727965) Phase III for Chronic Lymphocytic Leukemia (CLL).

  • Newest CDK Inhibitor

    NU6027 Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Product Information

  • Compare CDK Inhibitors
    Compare CDK Products
  • Research Area
  • Inhibition Profile

Product Description

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Targets CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
CDK2/CyclinE2 [1]
(Cell-free assay)

 View  More

IC50 9 nM 11 nM 15 nM >10 μM
In vitro PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MOLM13M3XyTmtqdmG|ZTDBd5NigQ>?M1\PNFI1KGh?MVTJcohq[mm2aX;uJI9nKEOGS{SgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDSZkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECyJO69VQ>?M2XIfFI1PjRzMUCz
COLO205MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVe3NkBpMU\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvODN4IN88US=>MYCyOFY1OTFyMx?=
U937MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWLuTFQxPzJiaB?=NITwPGRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMUSg{txOM3r5UFI1PjRzMUCz
MOLM13MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHnNdmY4OiCqNWn0U|l4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xOOTNiY3XscJMhcGG{Yn;ybY5oKE[OVEOgTXRFKG23dHHueEBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEm2JO69VQ>?NUTQXlNFOjR4NEGxNFM>
MOLM13MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYm3NkBpMX7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIPvdoFn\W6rYj3y[ZNqe3SjboSgbJVu[W5iTV;MUVE{KGOnbHzzJIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txOMl7nNlQ3PDFzMEO=
MDA-MB-435MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUDlNlZTOjRiaB?=NUXiPVBZUUN3ME2wMlE3KM7:TR?=NFjCdnQyPThyMUizNS=>
K562M1fRV2N6fG:2b4jpZ{BCe3OjeR?=MWq5OkBpMoK3SG1UVw>?NXjte4xtUUN3ME2yJO69VQ>?MlK5NlQ1OTd3Nk[=
DU145M2XjcmN6fG:2b4jpZ{BCe3OjeR?=NFXuepI6PiCqMoTrSG1UVw>?NXqxdYRoUUN3ME23MlUh|ryPM{Xwc|I1PDF5NU[2
MDA-MB-231Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVGxJO69VQ>?MlrSNlQhcA>?M{LtfWROW09?MnrVR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPlMXSyOFQyPzV4Nh?=
MCF7MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWjPTpRLOSEQvF2=NGDMUZUzPCCqNFH5UndFVVORNF7aR3ZE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U>M{SzXVI1PDF5NU[2
MCF7Moe5T4lv[XOnIFHzd4F6MV:1JO69VQ>?MY[yOEBpNGrFZXlFVVORM3rhVmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC=NWXSOI9MOjR2MUe1OlY>
MDA-MB-231NXPM[mJiU2mwYYPlJGF{e2G7NXTISpFyPSEQvF2=MWqyOEBpMWHEUXNQMUHJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFPET|Qw[3mlbHnuSFEh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBz\XSrbn;icIF{fG:vYTDwbI9{eGixconsZZRqd25iYYSgV4VzPzhyM3uxbVI1PDF5NU[2
MDA-MB-231NXfMOow5TnWwY4Tpc44hSXO|YYm=MkDYNU0yOCEQvF2=NWfZS4hUOjRiaB?=Ml7iSG1UVw>?MXXkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m|IHHzd4V{e2WmIHHzJHBCWlBiY3zlZZZi\2V?NGnYfm8zPDRzN{W2Oi=>
MCF7MXTGeY5kfGmxbjDBd5NigQ>?M3fnelEuOTBizszNNUToV2lXOjRiaB?=NUTLeopXTE2VTx?=M{XyNoRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMhWEGUUDDjcIVifmGpZR?=NG\Ib20zPDRzN{W2Oi=>
MDA-MB-231NICzNY5HfW6ldHnvckBCe3OjeR?=M4n1VFAvPS1zIN88US=>MVq0PEBpNVXwU2RNTE2VTx?=NUHaS|NUcGG|IH7vJGNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEB{fWJvR{GgdIhie2V?MmD2NlQ1OTd3Nk[=
MCF7MXfGeY5kfGmxbjDBd5NigQ>?Mo\YNE42NTFizszNMoDmOFghcA>?NGnIcIhFVVORMn7kbIF{KG6xIFPlcIwh[3mlbHWgZZJz\XO2IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDzeYIuTzFicHjhd4U>MXuyOFQyPzV4Nh?=
697NVHySpVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGXnW2NKSzVyPUG0PE4{QCCwTR?=NWP6SmZLW0GQR1XS
P12-ICHIKAWANUjSdpRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\Oc2lEPTB;OU[uNFQhdk1?MWXTRW5ITVJ?
NB69NIrLUolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUjTV3k4UUN3ME2xOlEvQCCwTR?=MY\TRW5ITVJ?
EoL-1NEPFXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmDPTWM2OD1zOEeuNlYhdk1?M{T6[XNCVkeHUh?=
BHT-101Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjlZVlKSzVyPUG5PE4zPSCwTR?=NELFOFRUSU6JRWK=
SK-NEP-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTJ{MD6wNkBvVQ>?NFflOmJUSU6JRWK=
MHH-NB-11M37aTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTOOmFKUUN3ME2yNlAvOTlibl2=M1\NPHNCVkeHUh?=
AsPC-1MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3Sco9kUUN3ME2yOVIvPTNibl2=MX\TRW5ITVJ?
ES1MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXhTWM2OD1{NU[uNlUhdk1?NWjGUVEzW0GQR1XS
LAMA-84MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2PsXGlEPTB;MkW4MlE6KG6PMVLTRW5ITVJ?
MOLT-16Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFvQUllKSzVyPUK1PE41QSCwTR?=M4fWOXNCVkeHUh?=
ES7NHjlT4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYjwXFVLUUN3ME2yO|MvODlibl2=NFrQeGVUSU6JRWK=
KY821MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jMdWlEPTB;M{G0MlEhdk1?M4n0dnNCVkeHUh?=
RT-112MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYX3RnVwUUN3ME2zNlEvODVibl2=MVLTRW5ITVJ?
HL-60MmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTN2MD62OkBvVQ>?MkPZV2FPT0WU
MOLT-4NXy1ZllwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{nP[2lEPTB;M{S1MlE{KG6PNVjVd2tLW0GQR1XS
KARPAS-45NVy1[nlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYLnUWh6UUN3ME2zO|YvOTZibl2=MnfqV2FPT0WU
SK-N-ASM4fLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfTfXVKSzVyPUO4O{45OyCwTR?=MUXTRW5ITVJ?
CTB-1Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XhcmlEPTB;NEC1MlAzKG6PMnOyV2FPT0WU
NKM-1MlS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTRzMT64PUBvVQ>?MWHTRW5ITVJ?
HTC-C3M{fSd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1T1Z2lEPTB;NEOyMlk2KG6PMWHTRW5ITVJ?
BE-13Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTR2ND6yO{BvVQ>?NYDDeG04W0GQR1XS
KOSC-2MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmqxTWM2OD12Nk[uPUBvVQ>?MoXoV2FPT0WU
NB14M2ntNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGrRfWVKSzVyPUS4N{42QCCwTR?=MXjTRW5ITVJ?
CAL-27M4myfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTR7ND61PUBvVQ>?MlHrV2FPT0WU
H9MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\WfWlEPTB;NEm1MlQ{KG6PMkTWV2FPT0WU
RS4-11MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTVyND63N{BvVQ>?NIrGVo9USU6JRWK=
PA-1MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTVyOT64OkBvVQ>?M1zWeXNCVkeHUh?=
MV-4-11NXL4Wml[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTVzMz64OUBvVQ>?MWTTRW5ITVJ?
OS-RC-2NGDUeFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTV{MT62NkBvVQ>?MkW3V2FPT0WU
RPMI-8226NG\sUYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGT4PIdKSzVyPUWyOk45PiCwTR?=MWPTRW5ITVJ?
HGC-27MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPrTWM2OD13NkSuPVkhdk1?Ml3aV2FPT0WU
CHP-212MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrhPHhKSzVyPUW5N{42QSCwTR?=Mne0V2FPT0WU
NB10MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWHhNZRHUUN3ME21PVkvOThibl2=NYj6R5lMW0GQR1XS
HHNGjLSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWH5R2hPUUN3ME21PVkvPDNibl2=MWTTRW5ITVJ?
EW-16NHr5UGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MojzTWM2OD14MEOuOVIhdk1?NYLGdVM6W0GQR1XS
ES8MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NITDcXBKSzVyPU[wOU4zOSCwTR?=M3Kzd3NCVkeHUh?=
HAL-01NGfyemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGrhWmxKSzVyPU[wOU43PyCwTR?=NIiyV21USU6JRWK=
A204MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTZ|Mz65NUBvVQ>?M1jjfnNCVkeHUh?=
MHH-PREB-1NHzTUWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vONGlEPTB;NkO2Mlk6KG6PNHG1emZUSU6JRWK=
EM-2MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlT1TWM2OD14NUCuOlQhdk1?MW\TRW5ITVJ?
BV-173NF;yWHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUD3dJRmUUN3ME22OVIvPDhibl2=M1jmOnNCVkeHUh?=
ONS-76MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mom0TWM2OD14N{euPFIhdk1?NH7kfHRUSU6JRWK=
KM-H2NUnD[nhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlTJTWM2OD14OUWuOVQhdk1?M3XSfXNCVkeHUh?=
D-263MGMn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkTITWM2OD15MUeuNVIhdk1?NVzTUVlOW0GQR1XS
ES3NXXESFM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY\pT|JTUUN3ME23NlgvQTNibl2=MUTTRW5ITVJ?
VA-ES-BJMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zNZmlEPTB;N{OyMlI4KG6PNVTnXohUW0GQR1XS
NBsusSRNYD5UoVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33idmlEPTB;N{SyMlk6KG6PMWTTRW5ITVJ?
NCI-H520MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmrlTWM2OD15NE[uOVIhdk1?NGPWNFNUSU6JRWK=
ES5MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfXO2xKSzVyPUe1Nk45KG6PMUPTRW5ITVJ?
T-24MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fP[GlEPTB;N{e4MlcyKG6PMkPZV2FPT0WU
SW962NFTSd4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnCTpNKSzVyPUiwPE43OyCwTR?=MULTRW5ITVJ?
EW-3MmG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXHeY9KSzVyPUiwPE44PiCwTR?=MkLGV2FPT0WU
RXF393MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHYTpFKSzVyPUixNk44QSCwTR?=NXTlVYNyW0GQR1XS
U251MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPGS5pSUUN3ME24NVMvQDhibl2=M4HpOXNCVkeHUh?=
CAMA-1NFHVNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXPI[4Z2UUN3ME24N|MvQTRibl2=M3P6RXNCVkeHUh?=
JVM-3M4\2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1y3WGlEPTB;OEWxMlc5KG6PMXLTRW5ITVJ?
COLO-800MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4Ty[WlEPTB;OEm3Mlc5KG6PM4H1SHNCVkeHUh?=
OVCAR-5NU\hbVRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXzxWXBDUUN3ME25NFAvOSCwTR?=NXzifFVqW0GQR1XS
LB1047-RCCNFXGSXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPudY1KSzVyPUmyO{42PiCwTR?=NID5cYRUSU6JRWK=
SW954M37lRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLGTWM2OD17MkmuOFEhdk1?NGrCfVdUSU6JRWK=
J-RT3-T3-5MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTl|Nj6wOkBvVQ>?M{LjfXNCVkeHUh?=
MewoM4jxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrCTWM2OD17M{[uOkBvVQ>?MoD6V2FPT0WU
NCI-H1770MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH3He4dKSzVyPUm0NE42PSCwTR?=NYrsNlBwW0GQR1XS
HO-1-N-1NEnhd|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTl4Mj64NUBvVQ>?M2nqUHNCVkeHUh?=
HSC-3NFvRUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\XZ2lEPTB;OU[2MlQ5KG6PM{PIOXNCVkeHUh?=
TYK-nuNIXjVopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTl7OD6yOUBvVQ>?NXzrdY5GW0GQR1XS
KYSE-150NUPPWlJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFr1RmxKSzVyPUGuNFAxPzZizszNM4qxSnNCVkeHUh?=
SN12CNHXmWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnDUmdGUUN3ME2xMlAxQDd3IN88US=>MoXLV2FPT0WU
MOLT-13MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkTZTWM2OD1zLkCxOFIyKM7:TR?=M{LzTnNCVkeHUh?=
TE-11Mlm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXXpcY9{UUN3ME2xMlA1QDF{IN88US=>MlrkV2FPT0WU
DBNH\OVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTFwMEeyO|Mh|ryPM4HvXXNCVkeHUh?=
CAL-39NVGwVpdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEXKNo5KSzVyPUGuNFc2OjJizszNNX\hdYl2W0GQR1XS
A3-KAWM130eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnn4TWM2OD1zLkC4OFA5KM7:TR?=M2r4RnNCVkeHUh?=
CHP-134NXXKcVFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTFwMUG4NFch|ryPMnz5V2FPT0WU
TGWMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1noNWlEPTB;MT6xNlM6PSEQvF2=NGXMSWtUSU6JRWK=
QIMR-WILMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH\MdW5KSzVyPUGuNVMyOzRizszNM{\mc3NCVkeHUh?=
NCI-SNU-1MmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTFwMU[zOVQh|ryPMV\TRW5ITVJ?
CGTH-W-1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\iUZBrUUN3ME2xMlE4OTh4IN88US=>MkjWV2FPT0WU
MHH-ES-1NY\2TGh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXkdmhNUUN3ME2xMlE4QTh4IN88US=>NFrQTY9USU6JRWK=
LB2241-RCCM3XlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3X1cmlEPTB;MT6xPFYzKM7:TR?=MU\TRW5ITVJ?
ML-2M4TsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTFwMkC3N|Qh|ryPM2L4OHNCVkeHUh?=
COR-L23M2Kw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEn3e3dKSzVyPUGuNlI6OzNizszNMoGyV2FPT0WU
BFTC-905NWTxbHJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1O0c2lEPTB;MT6yOFI3PyEQvF2=M3fqRnNCVkeHUh?=
Hs-578-TMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVG3WFBCUUN3ME2xMlI2QDF5IN88US=>NFj3VnpUSU6JRWK=
KG-1NYjlO5RsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2T0Z2lEPTB;MT6yOlY5PiEQvF2=MXrTRW5ITVJ?
HELMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TzXWlEPTB;MT6yPVM{QCEQvF2=MmrFV2FPT0WU
A549MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXS5N|hUUUN3ME2xMlI6Ozl7IN88US=>NXT0O25sW0GQR1XS
COLO-741MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTFwM{KwPFkh|ryPMWDTRW5ITVJ?
PC-3M{T2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1rTZWlEPTB;MT6zOVIzOSEQvF2=NGi2RZJUSU6JRWK=
HOSMmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInYW3JKSzVyPUGuN|UzQTZizszNNGH5fnNUSU6JRWK=
HT-1080NYLYVlhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPVTWM2OD1zLkO3OVE6KM7:TR?=MV3TRW5ITVJ?
TE-8Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XCO2lEPTB;MT60NVc4PCEQvF2=NEjVeGdUSU6JRWK=
BHYNX\lOIJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTFwNE[5NlMh|ryPMWfTRW5ITVJ?
BB65-RCCM2m1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4XyfWlEPTB;MT61NFUzQCEQvF2=MnHxV2FPT0WU
HNMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33lTmlEPTB;MT61OFA4OSEQvF2=M{jDTnNCVkeHUh?=
NCI-H441NWTiWVgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUfRO252UUN3ME2xMlU1QTB5IN88US=>MX7TRW5ITVJ?
RPMI-8866NUfGeWpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DJb2lEPTB;MT61PFUxPyEQvF2=M4DnXHNCVkeHUh?=
CAL-62NY\sZ3Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnzVTWM2OD1zLk[wPFYzKM7:TR?=MULTRW5ITVJ?
MG-63NXfKOGR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFX5cpZKSzVyPUGuOlE5OTNizszNM3LXS3NCVkeHUh?=
SK-LU-1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTFwNkKxOVIh|ryPMlXEV2FPT0WU
BCPAPMljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLwTWM2OD1zLk[2OFU4KM7:TR?=M3LwRXNCVkeHUh?=
22RV1Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWTHPGl4UUN3ME2xMlY4QDR|IN88US=>NHPqbopUSU6JRWK=
T47DMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHIe25JUUN3ME2xMlY5ODZzIN88US=>M{TTOHNCVkeHUh?=
MSTO-211HMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEPZVIVKSzVyPUGuOlk3ODNizszNMVrTRW5ITVJ?
DELMmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;qSpFFUUN3ME2xMlcxOjd|IN88US=>NGnZTXFUSU6JRWK=
H4NUXiWFhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGTnXW9KSzVyPUGuO|MzOTJizszNM2r0OnNCVkeHUh?=
CAL-51Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfUTWM2OD1zLke0PFU2KM7:TR?=MXzTRW5ITVJ?
ABC-1MnTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXq2U2RRUUN3ME2xMlc5PTh{IN88US=>M1POSHNCVkeHUh?=
MZ2-MELMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTFwN{m1OFIh|ryPM1K3OXNCVkeHUh?=
YKG-1NFrwZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLUUoRKSzVyPUGuPFExPjFizszNNXfWT5NWW0GQR1XS
KM12MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnHHTWM2OD1zLkixOlAzKM7:TR?=MXnTRW5ITVJ?
L-363NXntUFlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HHeGlEPTB;MT64O|QyOiEQvF2=MmDnV2FPT0WU
KU812NW\0fZV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\ZTJlKSzVyPUGuPFkzQDJizszNMWTTRW5ITVJ?
LOXIMVINYnHdG84T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlG4TWM2OD1zLkmxNlI5KM7:TR?=M4XiNHNCVkeHUh?=
G-401M1r5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTFwOUK0Nlgh|ryPNE\wOVRUSU6JRWK=
SW780MoqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTFwOU[yOFYh|ryPMVvTRW5ITVJ?
SW872NHPCdoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTFwOUizN{DPxE1?M1vnVXNCVkeHUh?=
NB7MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PpbmlEPTB;MT65PVMzOyEQvF2=M3zvVnNCVkeHUh?=
T98GMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYftXHhRUUN3ME2yMlAxPjZ4IN88US=>MXzTRW5ITVJ?
SW1710MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV7mOWxlUUN3ME2yMlA3QTR3IN88US=>NI\aR2FUSU6JRWK=
NCI-H1573NWqzTlJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojDTWM2OD1{LkC3Nlk5KM7:TR?=Mom0V2FPT0WU
KE-37MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3rLb2lEPTB;Mj6wPFk2OSEQvF2=NFfX[HBUSU6JRWK=
786-0M{T1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLmTWM2OD1{LkG1OFM6KM7:TR?=M1yyfHNCVkeHUh?=
SASNWj1[XN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjLbW5KSzVyPUKuNlA{PzRizszNNGLVUWlUSU6JRWK=
CAL-54Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTJwMkC0NVMh|ryPM1vpV3NCVkeHUh?=
SF268MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTJwMkOxNlIh|ryPNHzifnJUSU6JRWK=
SW620MoiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTJwMk[xOlkh|ryPNWrwNmdOW0GQR1XS
MN-60NVPDXo9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV\kU3NmUUN3ME2yMlMyODZizszNMoLiV2FPT0WU
EFO-27MmizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\4c2lEPTB;Mj6zNlA2QCEQvF2=MnPRV2FPT0WU
NCI-H747MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1HjdWlEPTB;Mj6zNlE6QSEQvF2=NEXVSoFUSU6JRWK=
HCC2218M2TIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXqNlZKSzVyPUKuN|U{PzRizszNNH[2dYhUSU6JRWK=
MIA-PaCa-2NF35VIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHSySZdKSzVyPUKuN|Y1OzdizszNNH\vSYtUSU6JRWK=
SJSA-1NE\ISGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFv3NJJKSzVyPUKuN|c4QTZizszNM1\mWHNCVkeHUh?=
RKOM{\MfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWLkW4lHUUN3ME2yMlM5PDl4IN88US=>M4fQOHNCVkeHUh?=
NB6M1Py[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLhTWM2OD1{LkSwN|c1KM7:TR?=NXS1RZBiW0GQR1XS
ES4MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTJwNEW0NlIh|ryPM1LuWXNCVkeHUh?=
EGI-1MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\qeGlEPTB;Mj60Olg5OyEQvF2=M2XNZXNCVkeHUh?=
CTV-1NU\lbIM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHOW4t5UUN3ME2yMlUzPzd|IN88US=>Ml70V2FPT0WU
NCI-H1355MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTJwNUW5OVEh|ryPM3n0bnNCVkeHUh?=
GT3TKBNV3MfJluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXpU4kyUUN3ME2yMlU6OTl7IN88US=>NInKfYRUSU6JRWK=
SK-HEP-1NV;C[3hXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLHfXl6UUN3ME2yMlU6OjZ4IN88US=>MWLTRW5ITVJ?
GAMGMoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnXWTWM2OD1{LkW5N|k1KM7:TR?=MYnTRW5ITVJ?
SK-MES-1M2GwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFy4bXJKSzVyPUKuOlE5ODNizszNM1qzb3NCVkeHUh?=
RO82-W-1MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfTTWM2OD1{Lk[yNFU4KM7:TR?=NYjw[nNXW0GQR1XS
ECC10NVvB[oRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXvTWM2OD1{LkewNlA3KM7:TR?=NGPNSWZUSU6JRWK=
MCF7NYDv[pJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTJwN{G0OlQh|ryPM16zXHNCVkeHUh?=
D-283MEDMmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTJwN{K0N{DPxE1?M{XwUXNCVkeHUh?=
RPMI-7951NYHNO254T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2X2UGlEPTB;Mj63OVY6PCEQvF2=MmDZV2FPT0WU
Ramos-2G6-4C10NFLDS2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTWWYdoUUN3ME2yMlc4ODl7IN88US=>M3[4XXNCVkeHUh?=
KGNNH;EVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTJwOEG4PFQh|ryPNXrGVpNYW0GQR1XS
NUGC-3NHv1NlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTJwOEK1NFUh|ryPMn;LV2FPT0WU
NCI-H292NHXxRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTJwOEWwOVMh|ryPMXjTRW5ITVJ?
BeckerM12x[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\tOGlKSzVyPUKuPVU5OzJizszNM1X1bnNCVkeHUh?=
NCI-H1299MkS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DTfGlEPTB;Mz6wOVI3OyEQvF2=NH3oWm9USU6JRWK=
ETK-1NF3jSWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHxbo1KSzVyPUOuNFU1OyEQvF2=NYCxbYhGW0GQR1XS
TK10MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGW4TJdKSzVyPUOuNlAyPjVizszNNVHTflhyW0GQR1XS
VMRC-RCZMlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGjHVHhKSzVyPUOuN|Y1QDhizszNMWPTRW5ITVJ?
YH-13MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTNwNESwO|kh|ryPMVHTRW5ITVJ?
DU-145MnfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH2xPINKSzVyPUOuOFYzPjlizszNMY\TRW5ITVJ?
SW1088Ml\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWG1S3JNUUN3ME2zMlQ4PDdizszNNXjkRm9[W0GQR1XS
HOP-92MnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HGR2lEPTB;Mz61NFM1OiEQvF2=MUXTRW5ITVJ?
KP-N-YSM3PiWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjC[5FYUUN3ME2zMlYzOTN7IN88US=>MYPTRW5ITVJ?
NCI-H460Ml7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVHqXFNsUUN3ME2zMlY3PzNizszNNIC4c4NUSU6JRWK=
U-2-OSM1Htdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnraTWM2OD1|LkeyOVM2KM7:TR?=NU\RZXNRW0GQR1XS
A101DNWjiS2VoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfNcnhEUUN3ME2zMlc3QTN4IN88US=>MnTRV2FPT0WU
MDA-MB-231MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPZOWNvUUN3ME2zMlgyQTVzIN88US=>M1r1RXNCVkeHUh?=
IST-MES1NYfuZVJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1G1OWlEPTB;Mz64N|Ih|ryPNVrEO2lyW0GQR1XS
COR-L105NHjwRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3O1WWlEPTB;ND6wNVgh|ryPNEHYdG5USU6JRWK=
NCI-H1437MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGnxXGlKSzVyPUSuNFI{ODJizszNM13JfnNCVkeHUh?=
CAL-85-1NG\xNHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTRwMEK0OlEh|ryPM2jYTXNCVkeHUh?=
MZ1-PCMnjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPQTWM2OD12LkG4OVU3KM7:TR?=MV\TRW5ITVJ?
VM-CUB-1MmTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfTVYlKSzVyPUSuN|EzQDRizszNNV3xS|U3W0GQR1XS
CHL-1NIXMOJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmTZTWM2OD12LkOyNVY6KM7:TR?=MkLNV2FPT0WU
MDA-MB-361M1mzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\0W2ZKSzVyPUSuN|MyPTNizszNMYHTRW5ITVJ?
NCI-H661MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkDvTWM2OD12LkWwNFkzKM7:TR?=Mk\iV2FPT0WU
EW-11Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn7ITWM2OD12LkWyNlMyKM7:TR?=MmK2V2FPT0WU
BENNHHEd|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTRTWM2OD12LkWyPFE2KM7:TR?=NECxbYVUSU6JRWK=
BFTC-909Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEK2XnJKSzVyPUSuOVYzPzVizszNMlXVV2FPT0WU
NCI-H2087NXjYcJd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXey[IxHUUN3ME20MlU5OTZ2IN88US=>NUn4eXFiW0GQR1XS
RVH-421MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\hTWM2OD12Lk[2Olkh|ryPM4XC[nNCVkeHUh?=
P30-OHKMlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTRwNkiwNFgh|ryPNV:1WHhqW0GQR1XS
NCI-H28NFSwcHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYroNoJVUUN3ME20MlgyPjZzIN88US=>NYf6VnVjW0GQR1XS
ES6NEXUcoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF3PVYdKSzVyPUSuPFMxOTZizszNNEnldXJUSU6JRWK=
769-PNGLkUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHO2U|lKSzVyPUSuPFU6OjZizszNNXmwXotWW0GQR1XS
OE33NYfYUnVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlrhTWM2OD12Lki4NVYyKM7:TR?=NV;sPHBYW0GQR1XS
SW982NIr5Z3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXfJR|UxRTRwOUWwOlEh|ryPNWHSRph{W0GQR1XS
A388MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTXTWM2OD13LkCyPVg{KM7:TR?=NETub4tUSU6JRWK=
TI-73MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIH5WotKSzVyPUWuNFYyQTRizszNNE[0Rm1USU6JRWK=
HCT-116MlSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2H6NmlEPTB;NT6wPVg5QSEQvF2=Mn;yV2FPT0WU
HuP-T3MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEPNXYVKSzVyPUWuNVg4ODlizszNNHLtcZlUSU6JRWK=
G-402NF3LbphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTVwMUm0NVYh|ryPMWDTRW5ITVJ?
NCI-H1792M1rTOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\LVIhrUUN3ME21MlI1PjJ{IN88US=>M4nZ[HNCVkeHUh?=
NCI-H209NILSbWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoD2TWM2OD13LkK1PVQzKM7:TR?=MnmyV2FPT0WU
NCI-H1650NXrwfnNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4rEPWlEPTB;NT6zNFY{PCEQvF2=M4rPd3NCVkeHUh?=
LCLC-97TM1NHXVbnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTVwM{G4NFgh|ryPNVPrU5p{W0GQR1XS
S-117NEm2OXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfzV4FwUUN3ME21MlM3QTd4IN88US=>M1;UTXNCVkeHUh?=
GI-ME-NNInkNIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDu[4lKSzVyPUWuN|k3QDFizszNNHzxeWtUSU6JRWK=
NCI-H2122M3nRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjOeZFYUUN3ME21MlQ6Ozl5IN88US=>MUPTRW5ITVJ?
NCI-H1793M4fnWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLVTWM2OD13Lk[3OVk{KM7:TR?=MXjTRW5ITVJ?
C2BBe1NGXYUVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTVwN{CwPFgh|ryPMVTTRW5ITVJ?
TE-12NFPORmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHny[JJKSzVyPUWuPFA2PTZizszNMlKyV2FPT0WU
LCLC-103HMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUL2SYhPUUN3ME21MlkyPyEQvF2=MX\TRW5ITVJ?
A673M3XnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIfZWodKSzVyPUWuPVE6OzJizszNMY\TRW5ITVJ?
BB30-HNCMmS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2LGd2lEPTB;NT65PFM3KM7:TR?=NI\SOplUSU6JRWK=
SF295MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTZwMEC0NlIh|ryPMXnTRW5ITVJ?
KU-19-19NHvaXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MojITWM2OD14LkCxO|MyKM7:TR?=NE\GO4NUSU6JRWK=
CFPAC-1MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDBW|RKSzVyPU[uNFQ1PDNizszNMo[xV2FPT0WU
LoVoNULiWHJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnlTWM2OD14LkC1NFY{KM7:TR?=MYTTRW5ITVJ?
8505CNXr2[HQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTEdY9sUUN3ME22MlA4PTd|IN88US=>NWP4[VZ[W0GQR1XS
GMS-10MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXKRXlSUUN3ME22MlE2ODB{IN88US=>MlS1V2FPT0WU
Ca9-22NEnSfYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TF[mlEPTB;Nj6xOlcyKM7:TR?=M3fRcHNCVkeHUh?=
DOKNVP6RVZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTZwMkKwO|Ih|ryPMV7TRW5ITVJ?
FADUNUfUT4MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTZwMk[wN|kh|ryPMYjTRW5ITVJ?
BxPC-3MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1LYOGlEPTB;Nj6yO|MzKM7:TR?=Mn7ZV2FPT0WU
CAL-33M1PTb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTR[5FXUUN3ME22MlI6OjBzIN88US=>NV\rU20{W0GQR1XS
SHP-77NVPoRlhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTZwM{G1NVIh|ryPMnnLV2FPT0WU
LXF-289MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mon5TWM2OD14LkOzOFU2KM7:TR?=NXPv[oVKW0GQR1XS
GB-1M37TcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDsfldKSzVyPU[uN|gzKM7:TR?=MWrTRW5ITVJ?
KS-1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTZwM{i0OFch|ryPNGLaVIxUSU6JRWK=
D-502MGNHX1UHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm\QTWM2OD14LkSyN|c3KM7:TR?=MXfTRW5ITVJ?
LAN-6MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M13GN2lEPTB;Nj61NVAzOyEQvF2=NELUfFVUSU6JRWK=
H-EMC-SSNGLFcYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTZwNU[xOFch|ryPM2DBfnNCVkeHUh?=
LC-2-adMnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{jJbGlEPTB;Nj62NFA4PiEQvF2=M{mzenNCVkeHUh?=
NCI-H1693NInHW41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{HyOmlEPTB;Nj62NlIyPSEQvF2=M3XZcnNCVkeHUh?=
SK-N-FINGnWcGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{W2WGlEPTB;Nj63OVA1PCEQvF2=MmXnV2FPT0WU
D-423MGNIfpUHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTZwN{[xNVch|ryPM4\qOHNCVkeHUh?=
KNS-42MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2LkOWlEPTB;Nj63PFE6PyEQvF2=MoWyV2FPT0WU
GCTMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFH1c5pKSzVyPU[uPVM5KM7:TR?=MkHxV2FPT0WU
DSH1NGnmeo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEXyRlZKSzVyPUeuNFY{OyEQvF2=M{S2UHNCVkeHUh?=
D-247MGM1zFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7G[oZsUUN3ME23MlA4QDhzIN88US=>M1fGbXNCVkeHUh?=
NCI-SNU-5MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LFRWlEPTB;Nz6xPFM4OSEQvF2=MYLTRW5ITVJ?
TE-6MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnNTWM2OD15LkKwOlAyKM7:TR?=M2LxT3NCVkeHUh?=
NOMO-1MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXWRWpKSzVyPUeuNlIyOjdizszNMkKwV2FPT0WU
NB17M2f5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1L2OmlEPTB;Nz6zNFMxQSEQvF2=NUD3[ppoW0GQR1XS
EW-22M3zWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYLSNYlkUUN3ME23MlM1OzR6IN88US=>MmnaV2FPT0WU
EW-13MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml2yTWM2OD15LkO1NVYzKM7:TR?=M3LSS3NCVkeHUh?=
DOHH-2MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXEZWdjUUN3ME23MlQ1ODJizszNMl\CV2FPT0WU
TGBC1TKBMkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH23SlFKSzVyPUeuOFk5QTlizszNNYnUPIxmW0GQR1XS
GR-STM37nc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGjBPXhKSzVyPUeuOVI2QTRizszNM1vTfHNCVkeHUh?=
KYSE-520NUW3cnlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3i5R2lEPTB;Nz61OVUyPSEQvF2=NHXxZWFUSU6JRWK=
CAPAN-1MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlTLTWM2OD15LkW5OVEh|ryPNHnPSYhUSU6JRWK=
HCE-4M{f0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mli2TWM2OD15Lk[yNlc6KM7:TR?=NF7qcGtUSU6JRWK=
MLMAM4LnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVqydXd2UUN3ME23MlYzQTV5IN88US=>MoSyV2FPT0WU
HT-144MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHxToF7UUN3ME23MlY2OzZ6IN88US=>NVzxbZJbW0GQR1XS
KYSE-180MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnH1TWM2OD15LkexNVY6KM7:TR?=NETrZ|NUSU6JRWK=
TE-5MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XsfGlEPTB;Nz65OVk4OSEQvF2=Mlv2V2FPT0WU
IGROV-1MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTdwOUi1OVEh|ryPNIjzSGpUSU6JRWK=
NCI-H1581NVyzdlNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1yyVmlEPTB;OD6wNVIh|ryPMojQV2FPT0WU
SW1990NIjvcXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF73bGlKSzVyPUiuNFQ3PTlizszNMnXuV2FPT0WU
EFM-19MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3S2PWlEPTB;OD6wPFU1PSEQvF2=MWTTRW5ITVJ?
OGR-1MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmr6TWM2OD16LkSzNFI{KM7:TR?=NWXweVBjW0GQR1XS
U-118-MGNX7lTGpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljUTWM2OD16LkSzOFY{KM7:TR?=MoTBV2FPT0WU
SK-OV-3NX25bnpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3vT5NmUUN3ME24MlQ3PzZ3IN88US=>NXe5T|NuW0GQR1XS
KNS-62NX\re45LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRThwNUG3OlEh|ryPMULTRW5ITVJ?
GOTONIfnRYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH7UT3VKSzVyPUiuOVc3OzVizszNNEHwPVRUSU6JRWK=
8305CMoq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVy1PVVbUUN3ME24MlcxPDh2IN88US=>M2\DUHNCVkeHUh?=
RPMI-2650M2XC[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFHhZ3JKSzVyPUiuO|E6PTVizszNNYjqWoNpW0GQR1XS
NEC8NYPISndHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoLsTWM2OD16Lke0N|A4KM7:TR?=NXXKcJVXW0GQR1XS
KYSE-450MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NED5bmJKSzVyPUiuPFY2PDhizszNMojQV2FPT0WU
RMG-IMlPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{TxfWlEPTB;OT6xOFA2QCEQvF2=MVnTRW5ITVJ?
CAKI-1M{Hvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTlwM{G5O|kh|ryPMUPTRW5ITVJ?
KYSE-510NGHuVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3WwdGlEPTB;OT6zOVc4QCEQvF2=NVT5UGNUW0GQR1XS
A4-FukM3e0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH:wc4tKSzVyPUmuN|Y4ODFizszNMUjTRW5ITVJ?
AN3-CAM331cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXRRlhKSzVyPUmuOFU1PDRizszNMYnTRW5ITVJ?
SK-N-DZM13JNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrMcVhKSzVyPUmuO|I5PDlizszNMnvyV2FPT0WU
HSC-2NV7VU|JCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEK3UGdKSzVyPUmuO|Y3OjlizszNNXrPeI52W0GQR1XS
EW-1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XSRmlEPTB;OT63PVM3QSEQvF2=MnHTV2FPT0WU
D-566MGNX\rRpVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXG0UIU3UUN3ME25Mlg{PjZ2IN88US=>NEfIN|NUSU6JRWK=
COLO-792NVPzeGY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTlwOUi3OFYh|ryPNXKxe45pW0GQR1XS
TE-10M4LxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkW3TWM2OD1zMD6wN|k3KM7:TR?=MmCxV2FPT0WU
NCI-H650M{\FT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnNUlFDUUN3ME2xNE41Ojh4IN88US=>NHXN[GxUSU6JRWK=
U-266NXXsNGhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHOwTFdKSzVyPUGwMlQ2PSEQvF2=MoPRV2FPT0WU
Detroit562M{f4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrBZVg6UUN3ME2xNU4xPTF3IN88US=>MoTEV2FPT0WU
NH-12NUP6dmUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFSyPWhKSzVyPUGxMlE1PDZizszNNV;HN3M1W0GQR1XS
CO-314MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTFzLkK4OFIh|ryPMX7TRW5ITVJ?
IST-MEL1M1Lvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3;BNmlEPTB;MUGuOVMzOyEQvF2=NIK1bJhUSU6JRWK=
KNS-81-FDM3O0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLHR2JKSzVyPUGxMlU2OjdizszNMYXTRW5ITVJ?
SW1463MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDibGJKUUN3ME2xNU42QTh7IN88US=>NUjJTXhrW0GQR1XS
NCI-H23M{XRZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTFzLk[1OVIh|ryPMXPTRW5ITVJ?
SK-MEL-2NXnxT|ZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTFzLkexPVch|ryPMWTTRW5ITVJ?
NB13MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTF{LkG0PVUh|ryPMn23V2FPT0WU
DaoyMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DVVGlEPTB;MUKuNlg2PiEQvF2=MmPZV2FPT0WU
NCI-H1623NVjyfGQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHMS|BnUUN3ME2xNk4{QDBzIN88US=>MnzFV2FPT0WU
NMC-G1NVy2cWFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XMO2lEPTB;MUKuO|E4KM7:TR?=MYfTRW5ITVJ?
DK-MGMlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUHoPVFPUUN3ME2xNk46PDh{IN88US=>MXHTRW5ITVJ?
TCCSUPMmPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWnob3BzUUN3ME2xN{4yOjh2IN88US=>NXO1WJU{W0GQR1XS
SCC-15NWP2U3A3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTF|LkK2OVEh|ryPNEHnTZpUSU6JRWK=
NOS-1MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{nHPGlEPTB;MUOuNlg6OyEQvF2=MYDTRW5ITVJ?
RH-1MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;P[IFqUUN3ME2xN{4{ODN5IN88US=>MXTTRW5ITVJ?
SK-MEL-3NIK3V|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTF|LkO3Nlgh|ryPM4CzdnNCVkeHUh?=
NB5NIezZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTF|LkSwOlch|ryPNHzWe2VUSU6JRWK=
SNU-387M4fXemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWP1eXlxUUN3ME2xN{42ODd{IN88US=>MWjTRW5ITVJ?
CAL-120MkDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jaO2lEPTB;MUOuOlcyQCEQvF2=NW\UcWhRW0GQR1XS
Mo-TNHm1OWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml:0TWM2OD1zMz63NFch|ryPNWrnb2tOW0GQR1XS
LNCaP-Clone-FGCNHTRVGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\YfGlEPTB;MUOuO|k6OiEQvF2=MULTRW5ITVJ?
CANNIntfYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\3TWM2OD1zND6wNlg5KM7:TR?=MkXsV2FPT0WU
SK-MEL-30M2HzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTF2LkC2N{DPxE1?NUjBZ3NTW0GQR1XS
COLO-678MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlvGTWM2OD1zND6wPFIzKM7:TR?=NGnyWVNUSU6JRWK=
SCC-9MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEPFTXBKSzVyPUG0MlExOjFizszNMYrTRW5ITVJ?
KINGS-1MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHufnYxUUN3ME2xOE4yPDB{IN88US=>NF\mO4tUSU6JRWK=
SL-513MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFr2[VRKSzVyPUG0MlE5PyEQvF2=NUm4NGNUW0GQR1XS
HLEMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjUTWM2OD1zND6zPFUzKM7:TR?=NHPxUYJUSU6JRWK=
SW1573NXnzfmFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTF2LkS0N|Uh|ryPNVPzRY9[W0GQR1XS
KYSE-140MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTF2Lk[zNlch|ryPNVTkPFZDW0GQR1XS
SK-PN-DWMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLr[o5KUUN3ME2xOE45ODBzIN88US=>NGj0PIVUSU6JRWK=
A253MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUD4NXloUUN3ME2xOU4xPjJ3IN88US=>NYrPS4M2W0GQR1XS
CAL-12TM2f0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDMTWM2OD1zNT60OlYzKM7:TR?=NIP6VmpUSU6JRWK=
COLO-679M3j3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TmSGlEPTB;MUWuO|Y5OyEQvF2=NGPCTI9USU6JRWK=
UACC-257NEnicGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2TXb2lEPTB;MU[uNVIxOSEQvF2=M2PDd3NCVkeHUh?=
U-87-MGMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTF4LkO1NlMh|ryPNHjoelBUSU6JRWK=
HCC1806M{PhOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{jqPGlEPTB;MU[uO|A4OSEQvF2=NEfzR5NUSU6JRWK=
NCI-H2170M3foV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlruTWM2OD1zNz6yOFQ5KM7:TR?=Mnn2V2FPT0WU
AGSNWewNFJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1vyUmlEPTB;MUeuN|gxQCEQvF2=NHmxXJNUSU6JRWK=
MEL-HOM3HyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF3weWlKSzVyPUG3Mlc2ODNizszNNHXaeYxUSU6JRWK=
SW48MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M13KfGlEPTB;MUeuO|cyPiEQvF2=M1zCSnNCVkeHUh?=
HuP-T4Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkflTWM2OD1zOD6wNlA3KM7:TR?=NF3BPXdUSU6JRWK=
NCI-H720Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmX0TWM2OD1zOD6xOFAzKM7:TR?=NUnNXnhnW0GQR1XS
RCC10RGBMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml7yTWM2OD1zOD6xOlk4KM7:TR?=MnPyV2FPT0WU
HD-MY-ZMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVf4PJI1UUN3ME2xPE4zOjV2IN88US=>MUHTRW5ITVJ?
A427MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXLoTJNZUUN3ME2xPE42ODl2IN88US=>MWfTRW5ITVJ?
HCC2998MkDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{C1cGlEPTB;MUiuOlA2OSEQvF2=MVHTRW5ITVJ?
EPLC-272HMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XRUGlEPTB;MUmuNFQ{PCEQvF2=MVzTRW5ITVJ?
C32MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{HTcGlEPTB;MUmuNFQ2KM7:TR?=NGnPSHZUSU6JRWK=
UMC-11M3n6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnDdGJmUUN3ME2xPU4zOTJ|IN88US=>NV7GVoNSW0GQR1XS
CaR-1MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\UeWlEPTB;MUmuOlgxPCEQvF2=MnnaV2FPT0WU
KYSE-410NGn6d41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mom0TWM2OD1zOT65NVM6KM7:TR?=NGrpWYRUSU6JRWK=
HuCCT1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjIe25FUUN3ME2yNE43Ojl2IN88US=>MnezV2FPT0WU
LB996-RCCMlvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULLOHVRUUN3ME2yNE44OTZ6IN88US=>M4iyT3NCVkeHUh?=
KYSE-70NXzRTYhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYW3PFl1UUN3ME2yNE45ODV7IN88US=>NF7CPXNUSU6JRWK=
CAL-72Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MknzTWM2OD1{MD65NVUh|ryPM4fDVnNCVkeHUh?=
Capan-2Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3viPWlEPTB;MkGuNFQyOyEQvF2=MkPLV2FPT0WU
PANC-08-13MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHRSmdyUUN3ME2yNU4zPTF3IN88US=>NYnxeI57W0GQR1XS
SBC-1Mk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHSOYRKSzVyPUKxMlMxQDFizszNNIXKfmpUSU6JRWK=
MFM-223MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETXZlZKSzVyPUKxMlM{PDJizszNM4nIZnNCVkeHUh?=
BB49-HNCMmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFHaZm1KSzVyPUKxMlU4OTZizszNNHTGVHlUSU6JRWK=
SH-4M4nFUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIf1b2JKSzVyPUKxMlY3OThizszNNVeyVHVHW0GQR1XS
HuO9NVniZ5lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3rBfGlEPTB;MkGuPVgzPSEQvF2=M3z4OHNCVkeHUh?=
AM-38NFf0UmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI\kXJRKSzVyPUKyMlA1QDVizszNMn3pV2FPT0WU
A431MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFfXOXhKSzVyPUKzMlIyOTlizszNMUfTRW5ITVJ?
YAPCM2HxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\XTIlKSzVyPUKzMlI3PTFizszNNInGXXlUSU6JRWK=
LU-139M1zPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWHMZ3VlUUN3ME2yN{41QDB7IN88US=>MYDTRW5ITVJ?
HEC-1M1zrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDkTWM2OD1{Mz60PVM4KM7:TR?=NXL4TFc4W0GQR1XS
SCC-25NULYc|g1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHG5OJNKSzVyPUK0MlMxODZizszNM3jw[nNCVkeHUh?=
HT-29NXmzVWtRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHnWdGVKSzVyPUK0MlM5OjNizszNM2fDU3NCVkeHUh?=
PC-14NWDnN2pET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPaTWM2OD1{ND62OVcyKM7:TR?=NXP5SJZRW0GQR1XS
Calu-6NVH6[IxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnjvTWM2OD1{NT61NFcyKM7:TR?=NHrtPGVUSU6JRWK=
SJRH30NG\3TWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV7wb5ROUUN3ME2yOU43PDl4IN88US=>NYKzUJdJW0GQR1XS
ChaGo-K-1MnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF24cWdKSzVyPUK2MlE3OjlizszNMYrTRW5ITVJ?
IA-LMMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MU\JR|UxRTJ4LkO2OFUh|ryPNYeyVlVZW0GQR1XS
GP5dMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1Tj[GlEPTB;Mk[uOFQ6OSEQvF2=MWXTRW5ITVJ?
NCI-H2291MmO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MljqTWM2OD1{Nj62OVQyKM7:TR?=M3vrWHNCVkeHUh?=
BALL-1M1riOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PTe2lEPTB;Mk[uPVM6PyEQvF2=MUPTRW5ITVJ?
HCC1954NVezRVVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPhXI9YUUN3ME2yOk46QDB6IN88US=>MmjnV2FPT0WU
NCI-H2452MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTJ5LkSxOlMh|ryPM2nuOXNCVkeHUh?=
LU-99AMmniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTJ5LkW1PFIh|ryPM{\w[HNCVkeHUh?=
NTERA-S-cl-D1NGf6NZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\p[mlEPTB;MkeuO|I6QSEQvF2=NGDmSlNUSU6JRWK=
PANC-10-05Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH7xVWhKSzVyPUK3Mlc4PzVizszNNXHGcI1SW0GQR1XS
NCI-H2405MkSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTJ5LkmzPFch|ryPNV3UeIVTW0GQR1XS
MDA-MB-415MlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jUWmlEPTB;MkiuOFE{PyEQvF2=NVSyfWdmW0GQR1XS
NCI-H2342NHjUNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYrzcJBNUUN3ME2yPE42OjhzIN88US=>NVvub5VFW0GQR1XS
TGBC24TKBNVO2VW5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4GyOGlEPTB;MkiuO|EyPyEQvF2=MnHMV2FPT0WU
LU-134-ANG\6WlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUjWWFNTUUN3ME2yPE46OjZzIN88US=>MWLTRW5ITVJ?
SCC-4M3vaVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\h[GlEPTB;M{GuNFQ6PCEQvF2=M1WxTXNCVkeHUh?=
Saos-2MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;4TWM2OD1|MT65N|A3KM7:TR?=MVvTRW5ITVJ?
RERF-LC-MSNVzvR|N1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4rFVmlEPTB;M{KuPFI{OSEQvF2=MofpV2FPT0WU
M14NHGxOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4HucWlEPTB;M{KuPVc3PCEQvF2=NYnZfoVUW0GQR1XS
HPAF-IIMkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkL3TWM2OD1|Mz61NFEyKM7:TR?=M3G0OXNCVkeHUh?=
NCI-H1755NWn0e4JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1T5PGlEPTB;M{SuN|MxPSEQvF2=Mmj2V2FPT0WU
D-392MGMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTN3Lki2O|Qh|ryPNV[1V5lsW0GQR1XS
A704MmrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTN4LkC0Nlch|ryPM1fIW3NCVkeHUh?=
CP50-MEL-BM17IS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTN4LkG5NVEh|ryPMV;TRW5ITVJ?
EW-18NF7MRXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\JcmlEPTB;M{[uOFUzKM7:TR?=MXjTRW5ITVJ?
WM-115MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTN4LkiwPVkh|ryPM3zRXnNCVkeHUh?=
LU-65Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUj3d5BXUUN3ME2zO{4yPDF5IN88US=>NXHONnhMW0GQR1XS
NCI-H1563MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\YOmhKSzVyPUO3MlI1QDRizszNMXLTRW5ITVJ?
DBTRG-05MGNHj1WoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTN6LkC2PVEh|ryPM{npOnNCVkeHUh?=
NCI-H630MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTN6LkS3NVQh|ryPMWHTRW5ITVJ?
NCI-H1155NY[1dmV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUfmbG5PUUN3ME2zPU4zPDJizszNNWrTUmtMW0GQR1XS
OVACR-3Ml3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTN7LkmxPVUh|ryPM{X3[XNCVkeHUh?=
OAW-42Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTRyLkSyOVgh|ryPMnO3V2FPT0WU
JVM-2MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTRzLkK0NVUh|ryPMl3DV2FPT0WU
C3AMmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2KwZWlEPTB;NEGuN|Q1PyEQvF2=MnLEV2FPT0WU
HT55MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnvvTWM2OD12Mj6yPFQyKM7:TR?=MYTTRW5ITVJ?
OVCAR-4NYXqeHB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHTycY9KSzVyPUSyMlI6PzRizszNM1;RSHNCVkeHUh?=
MEG-01NVvGeo5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\rTWM2OD12Mj60OlE3KM7:TR?=NXnxRm9QW0GQR1XS
NCI-H82NFHPcGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGrHfYtKSzVyPUSzMlk5QTJizszNNIfiWGlUSU6JRWK=
JEG-3NWnPPIh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHBTmVKSzVyPUS0Mlk1PyEQvF2=NYrxVXRnW0GQR1XS
BPH-1M2jne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXzo[5dvUUN3ME20Ok4{QTl6IN88US=>NHXmbZJUSU6JRWK=
MPP-89MkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXrdpdKSzVyPUS3MlI5QThizszNM1jFNnNCVkeHUh?=
ALL-POMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTR5LkSxPFgh|ryPM4H4U3NCVkeHUh?=
HTMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTR5LkS5NkDPxE1?NWPnUmVnW0GQR1XS
NCI-H2347NX;IT5FIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoL6TWM2OD12OD6wO|E2KM7:TR?=NXfhWppCW0GQR1XS
A2780NFfqN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2HEWGlEPTB;NEmuOFIzQCEQvF2=NI\VUohUSU6JRWK=
KARPAS-299NFPnO41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\lbWlEPTB;NEmuOVEyQSEQvF2=M1yzW3NCVkeHUh?=
NCI-H1651MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XsOWlEPTB;NEmuPFgzOSEQvF2=NEXSdGxUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).

Protocol(Only for Reference)

Kinase Assay: [1]

Cdk Assays A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.

Cell Assay: [1]

Cell lines Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
Concentrations 0.01-1 μM
Incubation Time 24 hours
Method Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.

Animal Study: [1]

Animal Models Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
Formulation Dissolved in sodium lactate buffer (50 mM, pH 4.0)
Dosages 0-150 mg/kg
Administration Given by gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Fry DW, et al. Mol Cancer Ther, 2004, 3(11), 1427-1438.

[2] Menu E, et al. Cancer Res, 2008, 68(14), 5519-5523.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-06-18)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02730429 Not yet recruiting Endometrial Cancer Nordic Society for Gynaecologic Oncology|ENGOT|GCIG August 2016 Phase 2
NCT02778685 Not yet recruiting Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Recurrent Breast Carcinoma|Stage IV Breast Cancer City of Hope Medical Center|National Cancer Institute (NCI) July 2016 Phase 2
NCT02738866 Not yet recruiting Metastatic Breast Cancer Sidney Kimmel Comprehensive Cancer Center|Pfizer July 2016 Phase 2
NCT02684032 Not yet recruiting Breast Cancer Pfizer June 2016 Phase 1
NCT02774681 Recruiting Breast Carcinoma Metastatic in the Brain|Estrogen Receptor Negative|HER2/Neu Negative|HER2/Neu Positive|Progesterone Receptor Negative|Recurrent Br  ...more Breast Carcinoma Metastatic in the Brain|Estrogen Receptor Negative|HER2/Neu Negative|HER2/Neu Positive|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma Northwestern University|Pfizer|National Cancer Institute  ...more Northwestern University|Pfizer|National Cancer Institute (NCI) May 2016 Phase 2

view more

Chemical Information

Download Palbociclib (PD-0332991) HCl SDF
Molecular Weight (MW) 483.99
Formula

C24H29N7O2.HCl

CAS No. 827022-32-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 3 mg/mL warming (6.19 mM)
Water 30 mg/mL (61.98 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo Saline 20 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 6-acetyl-8-cyclopentyl-5-methyl-2-(5-(piperazin-1-yl)pyridin-2-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one hydrochloride

Customer Product Validation(6)


Click to enlarge
Rating
Source Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck
Method Western Blot/Growth assay
Cell Lines OE33/OE19/Flo1A cells
Concentrations 125 nM
Incubation Time 1/3/21 day
Results PD-0332991 reduces expression of cyclinA in all 3 cell lines. PD-0332991 has no effect on the expression level of either total pRB or RB2 (p130) in EAC cells. PD-0332991 caused a significant reduction in colony formation in soft agar in all 3 cell lines tested, indicative of a reduction in anchorage independence.

Click to enlarge
Rating
Source Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck
Method Immunofluorescence
Cell Lines Patient tumor cell
Concentrations 3 uM
Incubation Time
Results Tumor organoids treated with VPA/ PD0332991 or SAHA/PD0332991 exhibited reduced structural integrity and increased cellular scatter with increasing concentrations of the drugs.

Click to enlarge
Rating
Source Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck
Method Immunofluorescence
Cell Lines Murine MSCs cells
Concentrations 2 uM
Incubation Time 24-48 h
Results We show that when cells are treated with PD332991 for 24–48 h there is a marked decrease in nuclear expression of cdk4 in PAX7- FKHR-expressing mMSCs. Further analysis by immunofluorescence showed that there is a minor upregulation in expression of MyoD1 in cells treated with cdk4 inhibitor for 48 h.

Click to enlarge
Rating
Source Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck
Method Western blot
Cell Lines WM3734 melanoma cells
Concentrations 0.25-4 μM
Incubation Time 36 h
Results

Click to enlarge
Rating
Source Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck
Method Western blot
Cell Lines T98G glioma cells
Concentrations 1 μM
Incubation Time
Results

Click to enlarge
Rating
Source Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck
Method IB analysis, Quantification of soft agar assays
Cell Lines LN319 cells
Concentrations
Incubation Time
Results

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related CDK Products

  • SU9516

    SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.

  • Ro-3306

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • Purvalanol A

    Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.

  • Palbociclib (PD0332991) Isethionate

    Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

    Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.

  • Dinaciclib (SCH727965)

    Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.

  • Flavopiridol (Alvocidib) HCl

    Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.

  • Roscovitine (Seliciclib,CYC202)

    Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.

  • LY2835219

    LY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.

  • Ribociclib (LEE011)

    Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.

  • SNS-032 (BMS-387032)

    SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. Phase 1.

Recently Viewed Items

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us